Trials / Completed
CompletedNCT02699073
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib. A GERCOR Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the performance of various tumor response criteria (Choi and RECIST1.1 criteria) in the assessment of regorafenib activity. Moreover, an assessment of the tumor heterogeneity will be made using computed tomographic texture analysis (CTTA)
Detailed description
This is a phase II study in patients with metastatic colorectal cancer treated by regorafenib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | regorafenib | 160mg once daily during 3 weeks followed by 1 week off therapy. Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity. |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2017-12-01
- Completion
- 2018-07-09
- First posted
- 2016-03-04
- Last updated
- 2019-02-28
Locations
8 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02699073. Inclusion in this directory is not an endorsement.